Can Pralsetinib effectively treat the disease?

Introduction: In September 2020, the U.S. Food and Drug Administration approved the first once-daily oral tyrosine kinase inhibitor pralsetinib for the treatment of patients with metastatic RET fusion-positive NSCLC. Pralsetinib has demonstrated response rates of 57% in patients who have previously received platinum-based chemotherapy and 70% in patients who have not received treatment.

RET fusions are found in 1%-2% of NSCLC, approximately 20% of papillary thyroid cancers, and <1% of many other solid tumors, including ovarian, pancreatic, salivary gland, and colorectal cancers.

Can the generic version of Pralsetinib also effectively treat diseases?

has basically the same therapeutic effectiveness as the original drug. Because the manufacture of generic drugs must follow the same active ingredients, dosage forms, administration routes and therapeutic effects as the original drug, it can also effectively treat related diseases.

It should be noted that due to differences in the production process, raw materials and production environment of generic drugs, the actual effects of generic drugs may also be different from the original drugs. When choosing to use a generic version of Platinib, patients should fully understand its efficacy and possible risks, and use it under the guidance of a doctor.

Pralsetinib (Pralsetinib) Treatment Effects

Since the approval of pralsetinib (Pralsetinib) and selpercatinib for the treatment of non-small cell lung cancer and thyroid cancer, treatment guidelines have recommended biomarker testing for RET mutations in patients with these tumor types. However, not all diseases in which RET mutations are considered drivers of cancer are standard treatments.

A total of 29 patients with 12 different types of RET fusion-positive solid tumors (excluding NSCLC and thyroid cancer) who had previously received standard therapy or were ineligible for standard therapy were recruited in one study. The most common RET fusion partners among the 23 patients evaluable for response were CCDC6 (26%), KIF5B (26%), and NCOA4 (13%).

Patients had an overall response rate (ORR) of 57%, with responses observed regardless of tumor type or RET fusion partner. The median duration of response, progression-free survival, and overall survival were 12 months, 7 months, and 14 months, respectively.

Pralsetinib usage and dosage

recommends that patients take 400 mg once a day. Patients should take oral medications on an empty stomach and should not eat at least 2 hours before taking the medication and at least 1 hour after taking the medication to avoid affecting the efficacy of the medication. If you forget to take a dose of Pralsetinib, take it as early as possible that day and resume your regular daily dosing schedule the next day. If vomiting occurs after taking this dose, do not take another dose, but continue with the next dose as planned.